Up­dat­ed: FDA sig­nals like­ly full ap­proval for Ei­sai's new Alzheimer's drug ahead of Fri­day's ad­comm

The FDA said Wednes­day that the con­fir­ma­to­ry tri­al that Ei­sai and Bio­gen ran to show their new Alzheimer’s drug has a clin­i­cal ben­e­fit did in­deed have one, lin­ing Leqem­bi up for a like­ly full ap­proval next month af­ter get­ting an ac­cel­er­at­ed nod in Jan­u­ary.

Ahead of Fri­day’s ad­vi­so­ry com­mit­tee meet­ing, which fea­tures just six vot­ing mem­bers, FDA re­view­ers af­firmed what Ei­sai and Bio­gen said at the time about the re­sults of the con­fir­ma­to­ry tri­al, known as CLAR­I­TY AD, adding that:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER